Summary
At this three day course, you will learn the basics about safety and pharmacovigilance in post-marketing surveillance and clinical trials. You will receive a comprehensive introduction to essential terminology and information sources as well as a thorough introduction to why and how clinical trials are performed.
The course also examines regulatory reports such as Periodic Safety Update Reports (PSUR) and Development Safety Update Reports (DSUR), product safety information and signal detection, interfaces with regulatory departments and with quality assurance about pharmacovigilance audits and inspections, and how to prepare for these.
Other course participants say
"I enjoyed the variety of lectures and the great presenters. The whole experience was very rewarding for me. I loved the structure of topics; it was easy and interesting to follow. I made very useful notes, and I am very sure I will use the provided slides in my future work."
Sabina Kujundzic, Pharm. D., Safety Data Associate, H. Lundbeck A/S
"The course had very good speakers, a nice venue, friendly atmosphere, and a good mix of relevant topics."
Anna Wanland, Market Access Manager, AcuCort AB
"It was an excellent course. I particularly liked that participants were both from the industry and authorities. It really showed that we have very similar tasks and interests and that we all share the same professional language. I now have a much better insight into the whole process of pharmacovigilance across development and post-marketing."
Mona El-Sayed Hervig, Pharmacovigilance officer, Lægemiddelstyrelsen
"A comprehensive and good course. A great way to get an understanding of PV as a newcomer to the field."
Gunilla Harm, Global Safety Specialist, LEO Pharma A/S
"Skilled and charismatic lecturers. Relevant presentations and introductions tovarious fields of pharmacovigilance."
Ann-Sofie Steen Brix, Associate Clinical Safety Professional, Novo Nordisk A/S
Keywords
- Danish and European Drug Safety Regulations
- The Danish Health and Medicines Authority
- The Individual Case Report
- Electronic Submission
- MedDRA
- Clinical Trial Directive 2001/20EC
- Non-Interventional Trials
- Risk Management Plans
Hi!
Do you need help choosing the right course?
We are ready to help you at +45 39 27 60 60 or contact@atriumcph.com
Save information for later
Course leader & lecturers
- Mette PhilipsenCourse leaderCluster Safety Lead
Pfizer ApS - Peter EriksenLecturerLead Specialist, Safety Scientist
H. Lundbeck A/S - Peter JelnesLecturerSenior Director, Safety Surveillance
Novo Nordisk A/S - Moritz SanderLecturerPharmacovigilance Officer
Lægemiddelstyrelsen - Helle Gerda OlsenLecturerPharmacovigilance officer
Lægemiddelstyrelsen - Berit Nautrup AndersenLecturerSafety Director
Link Medical Research, filial af Link Medical Research AS, Norge - Fida IssaLecturerSafety Surveillance Specialist
Novo Nordisk A/S - Janni HermansenLecturerDirector, Head of Global Safety Operations
Ferring Pharmaceuticals A/S - Mette Stie KallesøeLecturerHead of Pharmacovigilance QPPV
Hansa Biopharma AB - Jeannett DimsitsLecturerPartner
InnoStrat ApS - Jannik Høvring NielsenLecturerSafety Surveillance Principal Specialist, Global Safety
Novo Nordisk A/S - Kishore SahaLecturerChief Specialist - Global Patient Safety
H. Lundbeck A/S - Line Alleslev LarsenLecturerPrincipal safety advisor
LEO Pharma A/S - Elin PaulsenLecturerDrug safety Officer
Pfizer ApS - Heidi Filtenborg MadsenLecturerLead Specialist, Global Patient Safety
H. Lundbeck A/S
Watch the video
Is this course for you?
The course is for new employees in the pharmaceutical industry who want a general understanding of safety and pharmacovigilance, incl. risk management plans, crisis management, audits, and inspections. You will also benefit from the course if you work in a pharmacovigilance role, e.g. if you collaborate with people in clinical development on reporting side effects.
What you will learn
- The basic principles and elements of pharmacovigilance
- The essential terminology and information sources
- How to use best practices in drug safety and pharmacovigilance working processes
- How to prepare adverse event reports and the appropriate pharmacovigilance working methods
What your company will get
- A safety and pharmacovigilance professional who understands the basic principles and elements of pharmacovigilance
- A safety and pharmacovigilance professional who can operate in a dynamic and changing environment
- A safety and pharmacovigilance professional who can provide valuable input to all other team members working with drug safety and pharmacovigilance
Course calendar
Day 1
- Regulations and guidelines
- Qualified Person Responsible for Pharmacovigilance’s (QPPV) role and responsibility
- System master file
- Handling of Individual Case Study Report (ICSR), including licensing partners and pharmacovigilance (PV) agreements
- Product safety information
- Workshop
Day 2
- Periodic Safety Update Report (PSUR)
- Clinical development
- Clinical Trials Directive
- Non-interventional studies and post-authorization safety studies
- MedDRA coding
- Workshop
Day 3
- Development Safety Update Report (DSUR)
- Signal detection
- Crisis management
- Risk management plans
- Inspections
- How to prepare for audits and inspections
Registration
Registration deadline4 Nov 2024
Lersø Parkallé 101
2100 København Ø
Course information
Literature
Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.
Please familiarize yourself with the mandatory readings before starting the course
Examination
There is no examination for this course.
Course leader
Pfizer ApS
Lecturers
H. Lundbeck A/S
Novo Nordisk A/S
Lægemiddelstyrelsen
Lægemiddelstyrelsen
Link Medical Research, filial af Link Medical Research AS, Norge
Novo Nordisk A/S
Ferring Pharmaceuticals A/S
Hansa Biopharma AB
InnoStrat ApS
Novo Nordisk A/S
H. Lundbeck A/S
LEO Pharma A/S
Pfizer ApS
H. Lundbeck A/S
You may also be interested in these courses
13 Jan 2025
•
Want to know more or need help?
Contact Educational Programme Leader Lone Rex at +45 20 62 11 46
Send me a message